Welcome to our dedicated page for INSPIRE VETERINARY PARTNER SEC filings (Ticker: IVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inspire Veterinary Partners, Inc. (NASDAQ: IVP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, proxy statements, and registration statements. These documents offer detailed insight into IVP’s veterinary hospital operations, financial condition, risk factors, and capital structure.
Through recent Form 8-K filings, Inspire has reported material events such as notices from the Nasdaq Stock Market regarding minimum bid price compliance, the scheduling of a Nasdaq hearings panel review, changes in its independent registered public accounting firm, the issuance of senior convertible promissory notes, and equity issuances related to consulting agreements and debt cancellation. These filings explain key terms of financing arrangements, conversion features, and potential dilution, and they describe events of default and use of proceeds.
The company’s S-1 registration statements describe its business model as an owner and operator of veterinary hospitals across the United States, outline services offered at its clinics, and provide extensive risk factor disclosures covering profitability, acquisition strategy, regulatory exposure, internal controls, and listing considerations. Proxy materials on Schedule 14A detail matters submitted to stockholders, such as director elections and auditor ratification, and explain voting rights associated with Class A and Class B common stock.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly understand issues such as new debt or equity financings, changes in auditors, Nasdaq listing status, and governance matters. Users can review annual reports on Form 10-K and quarterly reports on Form 10-Q for comprehensive financial statements and management discussion, and monitor 8-Ks for real-time updates on significant corporate events. Insider ownership and equity incentive information can be explored through proxy statements and related filings.
By using this page, investors and researchers can efficiently navigate Inspire Veterinary Partners’ SEC reporting history, compare successive filings, and see how the company’s financial and regulatory profile develops over time.
Inspire Veterinary Partners, Inc. entered into a Cancellation and Exchange Agreement with Target Capital 1 LLC on December 18, 2025. Under this deal, the company cancelled $150,000 of outstanding principal on a June 10, 2025 promissory note in exchange for 3,000,000 shares of Class A common stock, based on a price of $0.05 per share. This transaction reduces debt while increasing the company’s share count.
The exchange and related offer of securities were completed as an unregistered private placement, relying on exemptions from registration under Section 3(a)(9), Section 4(a)(2), and Rule 506(b) of Regulation D. The full terms are set out in the Cancellation and Exchange Agreement filed as an exhibit.
Inspire Veterinary Partners, Inc. entered into a new Consulting Agreement with 622 Capital LLC on December 12, 2025. Under this agreement, the consultant will provide business development services focused on business financing opportunities.
As consideration for these services, Inspire Veterinary Partners agreed to issue an aggregate of 9,450,000 shares of its Class A common stock. Of this total, 3,300,000 shares were issued upon execution of the agreement, and an additional 6,150,000 shares are issuable within five business days after execution. These shares are being issued under the company’s 2022 Equity Incentive Plan and are registered on a Form S-8. The agreement also includes customary representations, covenants, indemnification, and confidentiality provisions and remains in effect until terminated according to its terms.
Inspire Veterinary Partners, Inc. has obtained written consent from stockholders holding 54.4% of the voting power to approve an amendment to its Amended and Restated Articles of Incorporation. This amendment will increase the number of authorized shares of Class A common stock from 100,000,000 to 700,000,000 shares. The approval was given by majority written consent in lieu of a stockholder meeting under Nevada law, so no vote or proxy from other stockholders is being solicited.
The amendment will become effective on the 20th calendar day after this information statement is first mailed or furnished and after the related Certificate of Amendment is filed with the Secretary of State of Nevada. As of December 9, 2025, the company had 38,567,465 shares of Class A common stock and 3,020,750 shares of Class B common stock outstanding, providing context for the scale of the new authorization. Stockholders do not have dissenter’s or appraisal rights in connection with this action.
Inspire Veterinary Partners, Inc. reported that Nasdaq has notified the company its common stock no longer meets the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) after 30 consecutive business days with a low closing bid price. Nasdaq stated the company’s securities would be suspended from trading on the Nasdaq Capital Market at the opening of business on November 24, 2025, and a Form 25-NSE would be filed to remove the securities from listing and registration, unless the company appealed. The company requested a hearing before Nasdaq’s Hearings Panel by November 20, 2025, which stays any suspension or delisting action during the process. On November 21, 2025, the company was informed that the hearing is scheduled for January 13, 2026, and it cautions there can be no assurance it will retain its Nasdaq listing or regain compliance.
Inspire Veterinary Partners, Inc. (IVP) has received a notice from Nasdaq stating that its common stock no longer meets the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The notice also explains that the company is not eligible for an automatic compliance period because it has completed reverse stock splits over the past one and two years with a cumulative ratio of 250 shares or more to one under Listing Rule 5810(c)(3)(A)(iv). Nasdaq has stated that IVP’s securities will be suspended from trading on the Nasdaq Capital Market at the opening of business on November 24, 2025, with a Form 25-NSE filed to remove the securities from listing and registration, unless the company appeals by November 20, 2025. IVP plans to request a hearing, which will temporarily halt the suspension or delisting process, but there is no assurance it will retain its Nasdaq listing.
Inspire Veterinary Partners (IVP) filed its Q3 2025 10‑Q, reporting quarterly revenue of $4,316,132, up modestly from $4,049,025 a year ago. The company posted a net loss of $2,526,273 for the quarter, improving from a $3,489,326 loss last year. For the nine months, revenue was $12,238,875 versus $13,270,973, with a net loss of $7,975,878 versus $10,297,539.
Total assets rose to $23,955,766 from $20,195,994, and stockholders’ equity increased to $4,168,681 from $1,562,005, aided by new financing. Cash used in operations was $3,555,276 year‑to‑date; cash, cash equivalents and restricted cash ended at $576,246. Interest expense was $559,111 in Q3 and $1,385,891 year‑to‑date.
The company disclosed “substantial doubt” about its ability to continue as a going concern due to recurring losses, an accumulated deficit of $44,326,158, and negative working capital of $5,894,301 as of September 30, 2025. IVP completed private placements of Series B preferred stock in July and September for approximately $6 million combined and recognized a $2,571,429 investment in equity securities. Nasdaq later confirmed compliance with its minimum stockholders’ equity requirement.
Inspire Veterinary Partners (IVP) entered a financing agreement, issuing two Senior Convertible Promissory Notes on November 5, 2025 to Keystone Capital Partners, LLC and Seven Knots, LLC. Each note has $178,571.43 principal with a 30% original issue discount, for a $125,000 purchase price per note, bears 10% annual interest paid monthly, and matures on August 5, 2026, unless earlier converted or repaid.
The notes are convertible at the holder’s option at a price equal to 90% of the lowest sale price over the 20 trading days before conversion, with an adjustment if the Company later issues at a lower price. A 4.99% beneficial ownership cap applies, adjustable up to 9.99% with notice. The Company must prepay 25% of gross proceeds from its existing equity line with Seven Knots at a 120% premium, and a $1,000,000 Qualified Financing triggers full repayment at a 120% premium. Upon default, amounts may be accelerated at 120% and interest increases to up to 24% per annum. Proceeds are for general working capital.
Inspire Veterinary Partners, Inc. will hold its 2025 Annual Meeting on December 10, 2025 at 10 a.m. ET as a virtual audio webcast. Stockholders will vote to elect seven directors and to ratify M&K CPAS, PLLC as the independent auditor for 2025. The Board recommends voting FOR all nominees and FOR auditor ratification.
The record date is October 14, 2025. As of that date, 3,647,610 Class A shares were outstanding (one vote per share) and 3,020,750 Class B shares were outstanding (25 votes per share), giving Class B holders 75,518,750 votes. A quorum requires at least 26,441,565 votes represented in person or by proxy.
On October 16, 2025, the company appointed M&K CPAS, PLLC and dismissed Kreit & Chiu CPA LLP. There were no disagreements reported; K&C previously identified material weaknesses in internal control, and its 2023–2024 audit reports included an explanatory paragraph on substantial doubt about going concern.
FAQ
What is the current stock price of INSPIRE VETERINARY PARTNER (IVP)?
What is the market cap of INSPIRE VETERINARY PARTNER (IVP)?
